Recovery

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide used in laboratory models of tissue-response, gastric, and signaling research.

Disclaimer: Information is for research and educational purposes only. Catalog materials are not approved for human or veterinary use.

BPC-157 is a synthetic fifteen-amino-acid peptide. The sequence is taken from a gastric protein often called Body Protection Compound. Literature from the early 1990s onward discusses it in experimental models of tissue response, angiogenesis-related markers, and gastrointestinal injury. It is not approved by the FDA for human use.41

Zeptix Labs supplies BPC-157 as a research-use-only material. Listings are for qualified laboratory, analytical, and preclinical research settings. They are not for human or veterinary use.

What the name refers to

“BPC” points to the parent protein context. The “157” marks this specific fragment. Catalog material is chemically synthesized to that sequence, then typically lyophilized. A COA should confirm identity and chromatographic purity for the lot in the vial, not a generic claim about the name.

Where it shows up in published work

Papers and reviews have examined BPC-157 in gastrointestinal, tendon, and inflammatory-signaling models, including work on nitric-oxide related pathways and rodent Achilles-tendon assays. Those studies are experimental. They do not convert a research peptide into a treatment.253

  • Tissue-remodeling and extracellular-matrix response models.
  • Gastric lining and intestinal-barrier research contexts.
  • Oxidative-stress and inflammatory-marker pathways, including some nervous-system models.

Related catalog items

Labs that compare recovery-theme peptides often look at TB-500 alongside BPC-157, or at the BPC-157 / TB-500 blend. GLOW and KLOW also include BPC-157 as one component of a multi-peptide research blend. Each SKU has its own lot paperwork.

BPC-157 from Zeptix Labs is for laboratory research only. It is not a drug, supplement, or material for administration.

Research context and evidence base

BPC-157 literature spans synthetic-peptide characterization, gastrointestinal models, tendon and muscle assays, and proposed nitric-oxide or growth-factor signaling. Most findings come from cells or animals. A useful review therefore separates the measured endpoint from broader claims and records the exact sequence, model species, tissue, comparator, and observation period.12

How to interpret the published evidence

Evidence should be sorted by study type before it is summarized. Analytical characterization establishes what material was tested; cell work can suggest pathways; animal models can explore integrated biology; and human studies, when they exist, apply only to their regulated product, population, and design. One layer should not be presented as if it proves the next.3

Experimental design questions

For BPC-157 work, controls may need to separate vehicle effects, baseline injury response, sequence-specific activity, and assay drift. Histology, migration, tensile strength, inflammatory markers, and pathway readouts are different endpoints; selecting one after seeing the data increases bias. A protocol should also state whether it is testing a proposed mechanism or attempting to reproduce a previously published observation.

Building a reproducible laboratory record

For work involving What Is BPC-157, record the supplier, SKU, lot number, labeled amount, receipt date, storage history, reconstitution conditions, concentration calculation, control material, instrument or assay version, and prespecified endpoint. Keep the matching certificate of analysis with the run record. These details make a result auditable and help distinguish biological variation from a handling or identity problem.

  • Match the exact compound, sequence, modification, and formulation to the cited methods.
  • Use positive, negative, and vehicle controls appropriate to the assay.
  • Define concentrations, time points, exclusions, and endpoints before reviewing results.
  • Report null and unexpected findings alongside the planned readouts.

Quality, limitations, and research-use status

A certificate of analysis supports lot traceability but does not establish a biological outcome. Investigators remain responsible for method suitability, independent confirmation when required, and compliance with institutional rules. Zeptix Labs materials are supplied for qualified laboratory research only and are not drugs, supplements, cosmetics, foods, or materials for human or veterinary administration.

Reporting results without overreach

When reporting What Is BPC-157, state what the experiment directly measured and keep interpretation within that boundary. Include model limitations, uncertainty, failed quality controls, and alternative explanations. Avoid turning preclinical observations into treatment language or assuming that a statistically significant marker change is biologically important. Clear limitations make the article more useful to researchers and prevent laboratory evidence from being mistaken for consumer guidance.

References

  1. Kowalski, Ł., et al. “Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review.” Pharmaceuticals 18, no. 2 (2025): 185. https://doi.org/10.3390/ph18020185
  2. Sikiric, P., et al. “Stable Gastric Pentadecapeptide BPC 157–NO-System Relation.” Current Pharmaceutical Design 20, no. 7 (2014): 1126–35. PMID 23755725. https://pubmed.ncbi.nlm.nih.gov/23755725/
  3. Chang, C. H., et al. “Oral Stable Gastric Pentadecapeptide BPC 157 Therapy in Muscle and Tendon Healing.” Pharmacological Reports 72, no. 1 (2020): 206–12. https://pubmed.ncbi.nlm.nih.gov/?term=Chang+BPC+157+Pharmacological+Reports+2020
  4. Sikiric, P., et al. “A New Gastric Juice Peptide, BPC. An Overview of the Stomach-Stress-Organoprotection Hypothesis and Beneficial Effects of BPC.” Journal of Physiology-Paris 87, no. 5 (1993): 313–27. PMID 8298609. https://pubmed.ncbi.nlm.nih.gov/8298609/
  5. Staresinic, M., et al. “Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocyte Growth.” Journal of Orthopaedic Research 21, no. 6 (2003): 976–83. PMID 14554208. https://pubmed.ncbi.nlm.nih.gov/14554208/
  6. Chang C-H, Kowalska A, Seiwerth S, et al. Oral stable gastric pentadecapeptide BPC 157 therapy in muscle and tendon healing. Pharmacological Reports . 2020;72(1):206–212. https://doi.org/10.1007/s43440-019-00004-4 https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/
  7. Sikiric P, Vukojevic J, Dominko K, et al. Brain–gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology . 2016;14(2):153–161. https://pubmed.ncbi.nlm.nih.gov/26471976/ https://pubmed.ncbi.nlm.nih.gov/27138887/
  8. Sikiric P, Seiwerth S, Gojkovic S, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances and ischemia–reperfusion injury. World Journal of Gastroenterology . 2022;28(1):23–46. https://doi.org/10.3748/wjg.v28.i1.23 https://pubmed.ncbi.nlm.nih.gov/35125818/
  9. Starešinić M, Sebečić B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth. J Orthop Res. 2003;21(6):976–983. https://doi.org/10.1016/S0736-0266(03)00110-4
  10. Sikirić P, Petek M, Rućman R, Seiwerth S, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327. https://doi.org/10.1016/0928-4257(93)90038-U
Catalog

Related products

Continue reading

Related articles